Literature DB >> 7745013

Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle.

E Zambrano1, A Olivares, J P Mendez, L Guerrero, L Díaz-Cueto, J D Veldhuis, A Ulloa-Aguirre.   

Abstract

In the present study we analyzed physiological changes in the relative distribution of FSH isoforms circulating under baseline conditions throughout the ovarian cycle as well as the forms discharged by GnRH stimulation from putative acutely releasable and reserve pituitary pools. Eight normally menstruating women underwent blood sampling on three occasions, once each during the presumptive early or midfollicular phase (FP), late follicular phase to midcycle (preovulatory phase; PO), and mid- to late luteal phase (LP) of the menstrual cycle. Blood samples were withdrawn at 10-min intervals for a total of 10 h before and after the iv administration of 10 and 90 micrograms GnRH. GnRH-stimulated FSH pulses were analyzed for secretory burst mass, secretory burst amplitude, integrated FSH concentrations, and endogenous FSH half-life by deconvolution. Serum FSH isoforms were separated by preparative chromatofocusing in 30 x 1-cm columns and identified by RIA of eluent fractions. The changes observed in serum FSH isoform distribution were then correlated with the corresponding secretory and clearance estimates of the released FSH molecules. In each phase of the menstrual cycle, a significant rise in serum FSH concentrations was observed after administration of the consecutive low and high dose GnRH pulses. The magnitude of the response in terms of secretory burst mass, secretory amplitude, and area of GnRH-induced FSH peaks was significantly higher during the PO. In all cycle phases, but particularly during the FP and PO, administration of the 90-micrograms GnRH dose elicited higher (1.4- to 1.7-fold) FSH secretory responses than the lower dose. Multiple parameter deconvolution of the GnRH-induced FSH pulses revealed that FSH molecules released in response to 10 micrograms GnRH at PO exhibited significantly (P < 0.01) shorter plasma half-lives (108 +/- 11 min) than those released during the follicular and luteal phases of the same menstrual cycles (apparent plasma half-life of FSH released at FP, 222 +/- 37 and 271 +/- 47 min for 10 and 90 micrograms GnRH-induced FSH pulses, respectively; LP, 244 +/- 41 and 198 +/- 40 min; P = NS, FP vs. LP) and in response to the high dose GnRH challenge at PO (276 +/- 40 min). Under all conditions studied, serum FSH charge isoforms were distributed along a pH range of 7.0 to less than 4.0.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745013     DOI: 10.1210/jcem.80.5.7745013

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle.

Authors:  Arianna Pacchiarotti; Cesare Aragona; Renzo Gaglione; Helmy Selman
Journal:  J Assist Reprod Genet       Date:  2007-07-26       Impact factor: 3.412

2.  Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants.

Authors:  E Zambrano; T Zariñán; A Olivares; J Barrios-de-Tomasi; A Ulloa-Aguirre
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

3.  Macro- and Micro-heterogeneity in Pituitary and Urinary Follicle-Stimulating Hormone Glycosylation.

Authors:  George R Bousfield; Vladimir Y Butnev; Monica A Rueda-Santos; Alan Brown; Aaron Smalter Hall; David J Harvey
Journal:  J Glycomics Lipidomics       Date:  2014

Review 4.  Follicle-Stimulating Hormone Glycobiology.

Authors:  George R Bousfield; David J Harvey
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

5.  Sequential (hFSH + recFSH) vs homogenous (hFSH or recFSH alone) stimulation: clinical and biochemical (cumulus cell gene expression) aspects.

Authors:  Timur Gurgan; Debbie Montjean; Aygul Demirol; Yves J R Menezo
Journal:  J Assist Reprod Genet       Date:  2014-03-18       Impact factor: 3.412

Review 6.  Role of glycosylation in function of follicle-stimulating hormone.

Authors:  A Ulloa-Aguirre; C Timossi; P Damián-Matsumura; J A Dias
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

7.  Biological activity and metabolic clearance of recombinant human follicle stimulating hormone produced in Sp2/0 myeloma cells.

Authors:  C K Chin; P R Schofield; D M Robertson; P P Gray; W Chotigeat; S M Mahler
Journal:  Cytotechnology       Date:  1996-06       Impact factor: 2.058

8.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

9.  Hypo-glycosylated human follicle-stimulating hormone (hFSH(21/18)) is much more active in vitro than fully-glycosylated hFSH (hFSH(24)).

Authors:  George R Bousfield; Vladimir Y Butnev; Viktor Y Butnev; Yasuaki Hiromasa; David J Harvey; Jeffrey V May
Journal:  Mol Cell Endocrinol       Date:  2013-12-01       Impact factor: 4.102

10.  In vitro biological-to-immunological ratio of serum gonadotropins throughout male puberty in children with insulin-dependent diabetes mellitus.

Authors:  Elisa Nishimura; Daniela Söderlund; Cecilia Castro-Fernández; Teresa Zariñán; Juan Pablo Méndez; Alfredo Ulloa-Aguirre
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.